Journal
ANALYTICAL AND BIOANALYTICAL CHEMISTRY
Volume 377, Issue 6, Pages 956-963Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00216-003-2199-0
Keywords
optical imaging; neoplasms, detection; fluorescence; contrast agents, activatible
Funding
- NATIONAL CANCER INSTITUTE [R33CA088365, P50CA086355, R21CA088365] Funding Source: NIH RePORTER
- NCI NIH HHS [CA88365, CA86355] Funding Source: Medline
Ask authors/readers for more resources
Optical imaging of specific molecular targets and pathways in vivo has recently become possible through continued developments in imaging equipment, reconstruction algorithms, and more importantly the availability of imaging reporter molecules. These reporter molecules encompass photoproteins expressed in vivo and exogenously administered probes detectable by fluorescence and/or bioluminescence imaging. One particularly enticing aspect of optical imaging is the ability to design activatible probes with inherent amplification. This review summarizes our experience in developing novel near-infrared fluorescent (NIRF) imaging agents that report on protease activities. These agents are designed to be biocompatible, highly activatible, and able to produce bright NIRF following protease cleavage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available